IDYA (IDEAYA Biosciences, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by IDYA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-09 | Briseno Andres Ruiz | Chief Accounting Officer | MIXED | — | — |
| 2026-06-18 | Malcolm Garret Hampton | Director | A | — | — |
| 2026-06-18 | Scott W Morrison | Director | A | — | — |
| 2026-06-18 | WENDY L YARNO | Director | A | — | — |
| 2026-06-18 | TERRY J ROSEN | Director | A | — | — |
| 2026-06-18 | CATHERINE J MACKEY | Director | A | — | — |
| 2026-06-18 | Jeffrey Stein | Director | A | — | — |
| 2026-03-02 | Jeffrey Stein | Director | Buy | — | — |
| 2026-02-02 | Darrin Beaupre | Chief Medical Officer | A | — | — |
| 2026-02-02 | MICHAEL ANTHONY WHITE | Chief Scientific Officer | A | — | — |
| 2026-02-02 | Douglas B. Snyder | SVP, General Counsel | A | — | — |
| 2026-02-02 | STUART DORMAN | Chief Commercial Officer | A | — | — |
| 2026-02-02 | Joshua Bleharski | Chief Financial Officer | A | — | — |
| 2026-02-02 | Yujiro S Hata | President and CEO | A | — | — |
| 2026-02-02 | Briseno Andres Ruiz | See Remarks | A | — | — |
| 2025-06-26 | Jeffrey Stein | Director | A | — | — |
| 2025-06-26 | TERRY J ROSEN | Director | A | — | — |
| 2025-06-26 | CATHERINE J MACKEY | Director | A | — | — |
| 2025-06-26 | Scott W Morrison | Director | A | — | — |
| 2025-06-26 | Malcolm Garret Hampton | Director | A | — | — |
| 2025-06-26 | WENDY L YARNO | Director | A | — | — |
| 2025-02-28 | Douglas B. Snyder | SVP, General Counsel | A | — | — |
| 2025-02-28 | Yujiro S Hata | President and CEO | A | — | — |
| 2025-02-28 | Darrin Beaupre | Chief Medical Officer | A | — | — |
| 2025-02-28 | MICHAEL ANTHONY WHITE | Chief Scientific Officer | A | — | — |
| 2025-02-28 | STUART DORMAN | Chief Commercial Officer | A | — | — |
| 2025-02-28 | Briseno Andres Ruiz | See Remarks | A | — | — |
| 2025-02-19 | Yujiro S Hata | President and CEO | M | — | — |
| 2024-09-27 | Douglas B. Snyder | SVP, General Counsel | A | — | — |
| 2024-06-27 | Jason Throne | Chief Legal Officer | M | — | — |
| 2024-05-31 | Malcolm Garret Hampton | Director | A | — | — |
| 2024-05-31 | CATHERINE J MACKEY | Director | A | — | — |
| 2024-05-31 | Susan L. Kelley | Director | A | — | — |
| 2024-05-31 | TERRY J ROSEN | Director | A | — | — |
| 2024-05-31 | Jeffrey Stein | Director | A | — | — |
| 2024-05-31 | Scott W Morrison | Director | A | — | — |
| 2024-05-31 | WENDY L YARNO | Director | A | — | — |
| 2024-05-31 | MICHAEL ANTHONY WHITE | Chief Scientific Officer | MIXED | — | — |
| 2024-05-16 | Yujiro S Hata | President and CEO | MIXED | — | — |
| 2024-03-04 | Darrin Beaupre | Chief Medical Officer | A | — | — |
| 2024-03-04 | Yujiro S Hata | President and CEO | A | — | — |
| 2024-03-04 | Briseno Andres Ruiz | See Remarks | A | — | — |
| 2024-03-04 | MICHAEL ANTHONY WHITE | Chief Scientific Officer | A | — | — |
| 2024-03-04 | Jason Throne | Chief Legal Officer | A | — | — |
| 2024-02-13 | Briseno Andres Ruiz | See Remarks | Sell | — | — |
| 2024-02-12 | Yujiro S Hata | President and CEO | MIXED | — | — |
| 2024-02-05 | Yujiro S Hata | President and CEO | MIXED | — | — |
| 2024-01-24 | Briseno Andres Ruiz | See Remarks | Sell | — | — |
| 2024-01-17 | Briseno Andres Ruiz | See Remarks | Sell | — | — |
| 2024-01-17 | Yujiro S Hata | President and CEO | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 2,260,713 | — |
| — | 10%+ Owner | 2,260,713 | — |
| — | — | 1,642,186 | — |
| — | 10%+ Owner | 1,204,981 | — |
| — | President and CEO | 690,695 | — |
| — | 10%+ Owner | 382,384 | — |
| — | SVP, Chief Technology Officer | 127,853 | — |
| — | Chief Financial Officer | 127,824 | — |
| — | 10%+ Owner | 91,142 | — |
| — | Director | 84,420 | — |
| — | 10%+ Owner | 84,420 | — |
| — | SVP, Chief Scientific Officer | 80,289 | — |
| — | Director | 57,644 | — |
| — | Chief Accounting Officer | 36,016 | — |
| — | Chief Legal Officer | 16,424 | — |
| — | SVP, General Counsel | 1,039 | — |
| — | Chief Scientific Officer | 851 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IDYA quote page; the site-wide leaderboard is on the insider transactions hub.